Apixaban is an anticoagulant indicated for a large array of coagulation related conditions including:
Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
ATC4: B01AF
Strengths: 2.5mg & 5mg
Dosage Form: Tablets
Dossier in CTD format is available for submission
Out-licensing: offered for all international markets
* Product availability is subject to patent restrictions in countries where applicable patents are in effect
